EPCAM and neoplasm: More specifically for GC, while EpCAM-CAR T cells alone reduced or eliminated tumor burden but were susceptible to relapse, bispecific CAR T cells targeting EpCAM and ICAM-1 significantly prevented relapse and decreased tumor size in gastric, lung, breast, and pancreatic cancer [79].